Discovery Service Flyer
WuXi Biologics
Offering End-to-End Solutions
Bioconjugation Discovery
Extensive R&D capabilities and world-class expertise
Extensive R&D capabilities and world-class expertise is available at WuXi XDC to generate, engineer, evaluate and optimize antibody drug conjugate (ADC)/bioconjugate lead candidates including trouble-shooting and overcoming the challenges associated with complex bioconjugated moieties. Wide-ranging R&D of the bioconjugation key intermediates, including mAb/protein, payload and linkers, is also available and is a cornerstone of the WuXi XDC technology platform.
Bioconjugation Discovery Services & Capabilities Overview
Conjugation Capabilities
The discovery services team at WuXi XDC applies multiple methods for the synthesis of bioconjugates between payloads and macromolecules that include proteins (e.g., antibodies, fusion proteins), peptides, and polynucleotides, amongst others. We use many types of conjugation technologies including traditional cysteine- and lysine-conjugation, and many of the widely used site-directed conjugation methods such as THIOMAB™, non-natural amino acid incorporation, and glycol site- and enzyme-assisted conjugation. Our bioconjugation experience encompasses multiple carriers and an extensive linker and payload library is available for your R&D purposes as demonstrated in the table:
Comprehensive Capabilities and Vast Project Experiences from ADC to XDC
From ADC to XDC, the boundaries of bioconjugates are continually expanding. At WuXi XDC, we have conducted a vast array of projects across bioconjugation landscape. Our capability from ADCs to XDCs:
Related Resource
Discovery Service Flyer
Scientific Poster
Antibody–Oligonucleotide Conjugates
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?